Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Financing Activities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash from Financing Activities for 6 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 99.84% to $73000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$336000.0 through Dec 2025, down 100.16% year-over-year, with the annual reading at -$336000.0 for FY2025, 100.16% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $73000.0 at TScan Therapeutics, down from $116000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $161.6 million in Q2 2024, with the low at -$686000.0 in Q2 2021.
  • Average Cash from Financing Activities over 5 years is $25.1 million, with a median of $116000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities skyrocketed 9060700.0% in 2021, then crashed 303.49% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $120000.0 in 2021, then fell by 10.0% to $108000.0 in 2022, then tumbled by 82.41% to $19000.0 in 2023, then skyrocketed by 240373.68% to $45.7 million in 2024, then plummeted by 99.84% to $73000.0 in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $73000.0, $116000.0, and -$525000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.